-
Journal of Asthma and Allergy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Demographic disparities in patient-reported use of inhaled corticosteroids among patients with persistent asthma
Original Research
(1849) Views (379) Full article downloads
Authors: Varun Vaidya, Monica Holiday-Goodman, Sharrel Pinto
Published Date August 2010
Volume 2010:3 Pages 101 - 106
DOI: http://dx.doi.org/10.2147/JAA.S11683
Varun Vaidya, Monica Holiday-Goodman, Sharrel PintoPharmacy Health Care Administration, Department of Pharmacy Practice, University of Toledo, Ohio, USA
Background: Despite the presence of existing guidelines, underuse of inhaled corticosteroids (ICSs) still exists among patients with persistent asthma in the United States. Inappropriate utilization of asthma medications has been attributed as one of the reasons for the significant economic burden due to asthma.
Objectives: To determine the demographic factors predicting patient-reported use of ICSs among patients with asthma.
Methods: The study utilized data from the 4-state sample of the National Asthma Survey (NAS), sponsored by the National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC). The study population consisted of patients with persistent asthma as defined by National Heart, Lung, and Blood Institute (NHLBI) guidelines. Frequency distributions were made to characterize the study population. Logistic regression analysis was carried out to determine the odds of reported use of ICSs across various demographic variables (age, gender, race, income level, insurance coverage, and disease severity). Data were analyzed using SAS v9.0 software.
Results: Underutilization of ICSs was found to exist in the patients with asthma, as more than half of the study population (52.8%, n = 304) did not report the use of ICSs. African American patients were found to have much lower odds for use of ICSs (odds ratio [OR] = 0.495; confidence interval [CI], 0.248–0.987) when compared with whites. Insured patients had significantly higher odds for the use of ICSs (OR = 2.378; CI, 1.106–5.110) compared with uninsured patients. The findings held true even after adjusting for other demographic factors.
Conclusion: Underuse of ICSs continues to be a problem in patients with asthma. Vulnerable populations identified in this study are targeted for the use of ICSs. The importance of adherence to treatment and use of ICSs is an issue that needs to be addressed.
Keywords: inhaled corticosteroids, asthma, demographics
Other articles by Dr Varun Vaidya
Utilization of preventive care services and their effect on cardiovascular outcomes in the United States
Readers of this article also read:
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone
Viral asthma: implications for clinical practice
The impact of food allergy on asthma
A systematic review of economic evaluations of therapy in asthma
Immunological and genetic aspects of asthma and allergy
Effect of household pet ownership on infant immune response and subsequent sensitization
The impact of asthma on the gastrointestinal tract (GIT)
Clinical update on the use of biomarkers of airway inflammation in the management of asthma
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions




